Relmada Therapeutics is dedicated to improving the standard of care for central nervous system (CNS) disorders. The company focuses on advancing its ongoing Phase 3 program of REL-1017, which aims to offer a treatment for major depressive disorder (MDD).

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

COM:RELMADA

Relmada Therapeutics, Inc.

Last Close

3.50

31/10 20:00

Market Cap

128.54M

Beta: -

Volume Today

67.59K

Avg: -

locale

market

industry

website

ipo date

peer of

Metrics